This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2009 Jul;56(1):103-4.

doi: 10.1016/j.eururo.2009.02.023. Epub 2009 Feb 27.

Editorial comment on: A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer

Henk G van der Poel

PMID: 19282103
DOI: 10.1016/j.eururo.2009.02.023

Editorial

Editorial comment on: A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer

Henk G van der Poel. Eur Urol. 2009 Jul.

. 2009 Jul;56(1):103-4.

doi: 10.1016/j.eururo.2009.02.023. Epub 2009 Feb 27.

Author

Henk G van der Poel

PMID: 19282103
DOI: 10.1016/j.eururo.2009.02.023

No abstract available

PubMed Disclaimer

Comment on

A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer.
Szmulewitz R, Mohile S, Posadas E, Kunnavakkam R, Karrison T, Manchen E, Stadler WM. Szmulewitz R, et al. Eur Urol. 2009 Jul;56(1):97-103. doi: 10.1016/j.eururo.2009.02.022. Epub 2009 Feb 27. Eur Urol. 2009. PMID: 19282098 Free PMC article. Clinical Trial.

Similar articles

Re: Russell Szmulewitz, Supriya Mohile, Edwin Posadas, et al. A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol 2009;56:97-104.
Friedman AE. Friedman AE. Eur Urol. 2009 Nov;56(5):e36; author reply e37. doi: 10.1016/j.eururo.2009.07.052. Epub 2009 Aug 12. Eur Urol. 2009. PMID: 19683856 No abstract available.
[Androgen deficiency in males and its correction in respect to pathogenesis of prostatic cancer].
Mazo EB, Grigor'ev ME, Konorev VA, Ermisheva OM. Mazo EB, et al. Urologiia. 2008 May-Jun;(3):57-8, 60-2. Urologiia. 2008. PMID: 18669351 Review. Russian. No abstract available.
Prevention of prostate cancer by androgens: experimental paradox or clinical reality.
Algarté-Génin M, Cussenot O, Costa P. Algarté-Génin M, et al. Eur Urol. 2004 Sep;46(3):285-94; discussion 294-5. doi: 10.1016/j.eururo.2004.04.012. Eur Urol. 2004. PMID: 15306098 Review.
Prostate cancer after exogenous testosterone replacement therapy in a patient with pituitary insufficiency.
Halland A, Jønler M, Pedersen KV. Halland A, et al. Scand J Urol Nephrol. 2005;39(1):87-8. doi: 10.1080/00365590410002546. Scand J Urol Nephrol. 2005. PMID: 15764279
Re: Michael J. Morris, Daisy Huang, William K. Kelly, et al. Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate. Eur Urol 2009;56:237-44.
Drewa T, Chlosta P. Drewa T, et al. Eur Urol. 2010 Feb;57(2):e18-9; author reply e20. doi: 10.1016/j.eururo.2009.10.021. Epub 2009 Oct 20. Eur Urol. 2010. PMID: 19853990 No abstract available.

See all similar articles

Cited by

Editorial Comment: Testosterone replacement therapy (TRT) and prostate cancer: An updated systematic review with a focus on previous or active localized prostate cancer.
Javaroni V. Javaroni V. Int Braz J Urol. 2022 Jan-Feb;48(1):188-195. doi: 10.1590/S1677-5538.IBJU.2022.01.08. Int Braz J Urol. 2022. PMID: 34735092 Free PMC article. No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information